Vetchy David, Vetcha Martina, Rabiskova Miloslava, Gryczova Eva, Bartosikova Lenka
Department of Pharmaceutics, Faculty of Pharmacy, Brno University of Veterinary and Pharmaceutical Sciences, Brno, Czech Republic.
Medicina (Kaunas). 2007;43(4):326-31.
After patent protection of original brand is over, there are a lot of generic products occurring on the pharmaceutical market. It may be the way to reduce the price, but on the other hand, one should expect the same quality and almost identity with original brand, because the development of generic drugs is based on pharmacological properties of the original brand. The aim of this study was to compare the similarity of two products with controlled release of felodipine--generic product Presid and original brand Plendil--which are commercially available in Czech Republic, based on in vitro dissolution testing. The dissolution test in three dissolution media of increasing pH (1.2, 4.5, and 6.5) for the simulation of physiological pH within the gastrointestinal tract confirmed controlled release of felodipine from the original product Plendil ER 5 mg and Plendil ER 10 mg during the period of 24 hours. The release of felodipine from generic products Presid 5 mg and Presid 10 mg was not controlled for 24 hours as it is indicated in the information leaflet. In the generic products, felodipine release was controlled just for 12 or 18 hours and in this respect did not show similarity with the original brand. Since patients take the drug just once a day in the morning, the controlled release of felodipine, which lasts only 12 to 18 hours, can cause insufficient blood pressure control especially in the most critical morning hours and higher cardiovascular risk.
原研品牌的专利保护期结束后,药品市场上出现了许多仿制药。这或许是降低价格的一种方式,但另一方面,人们应该期待仿制药与原研品牌具有相同的质量且几乎完全相同,因为仿制药的研发是基于原研品牌的药理特性。本研究的目的是基于体外溶出度测试,比较两种非洛地平缓释产品——仿制药Presid和原研品牌Plendil(在捷克共和国可商业获取)的相似性。在三种pH值递增(1.2、4.5和6.5)的溶出介质中进行溶出试验,以模拟胃肠道内的生理pH值,结果证实原研产品Plendil ER 5 mg和Plendil ER 10 mg中的非洛地平在24小时内实现了缓释。仿制药Presid 5 mg和Presid 10 mg中的非洛地平释放情况在24小时内未得到控制,这与药品说明书中的描述不符。在仿制药中,非洛地平的释放仅控制了12或18小时,在这方面与原研品牌不相似。由于患者每天只需在早晨服用一次药物,非洛地平仅持续12至18小时的缓释可能导致血压控制不足,尤其是在最关键的早晨时段,从而增加心血管风险。